Beam Therapeutics price target raised to $41 from $37 at Bernstein

Bernstein raised the firm’s price target on Beam Therapeutics (BEAM) to $41 from $37 and keeps an Outperform rating on the shares. The firm raised its price target following last week’s positive regulatory update on the Alpha-1 Antitrypsin Deficiency program. While Last week’s regulatory event was the main 2026 stock catalyst the firm was playing for, there are still several important events to track through the year end, including updated AATD data in Q126, the analyst tells investors in a research note.